Not Signed In -
Child Behavior Disorders |
Bullying |
Clinical Trial: A behavioral trial for the treatment of methamphetamine dependence. - 1
This study is no longer recruiting patients.
Purpose
The purpose of this study is to examine behavioral treatment for methamphetamine dependence.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Substance-Related Disorders | Behavior: Behavior Therapy | Phase II |
MedlinePlus related topics: Drug Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Uncontrolled
Official Title: Behavioral Trial for the Treatment of Methamphetamine Dependence
Expected Total Enrollment: 50
Study start: July 2001; Study completion: June 2002
To characterize meth. withdrawal symptoms using a multidimensional withdrawal questionnaire; to field test and investigate the effect of using an algorithm developed for discriminating between new use and residual carry-over of meth metabolites in urine and to evaluate the treatment response of meth. users to participation in the thrice weekly psychosocial protocol to be used as a "platform" in future pharmacotherapy trials.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Male or Female at least 18 yrs of age; DSM-4 diagnosis of methamphetamine (METH) dependence; be willing to comply with study procedures; verbalize understanding of consent and provide written consent and willingness to complete study procedures; be seeking treatment for METH dependence.
Exclusion Criteria:
Additional criteria available during screening at the site.
Location Information
California
Matrix Institute on Addictions, Costa Mesa, California, 92627, United States
South Bay Treatment Center, Chula Vista, California, 91911, United States
Hawaii
John A. Burns School of Medicine, Honolulu, Hawaii, 96813, United States
Iowa
Powell Chemical Dependency Center, Des Moines, Iowa, 50316, United States
Missouri
Comprehensive Mental Health Services, Inc, Independence, Missouri, 64052, United States
Richard Rawson, Ph.D., Principal Investigator, National Institute on Drug Abuse (NIDA)
More Information
Record last reviewed: August 2003
Last Updated: November 18, 2004
Record first received: April 5, 2002
ClinicalTrials.gov Identifier: NCT00033124
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
email this page
print this page
bookmark this page
feedback on this page
